Blinatumomab granted Priority Review in acute lymphoblastic leukemia

FDA granted priority review to the investigational bispecific T-cell engager antibody construct blinatumomab for the treatment of adults with Philadelphia-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.\

Amgen, the drug’s sponsor, also submitted a marketing authorization application to the European Medicines Agency. The submissions include data from a phase II trial of adult patients with Ph- relapsed/refractory B-precursor ALL treated with blinatumomab, which met its primary endpoint.

Blinatumomab, the first of Amgen’s investigational BiTE antibody constructs, has received orphan drug designation from the EMA and FDA, and breakthrough therapy and priority review designation from the FDA for the treatment of ALL.

Blinatumomab is designed to direct T cells against target cells expressing CD19, a protein found on the surface of B-cell derived leukemias and lymphomas. Blinatumomab is also being investigated in pediatric relapsed/refractory ALL, relapsed/refractory Philadelphia positive B-precursor ALL, minimal residual disease positive B-precursor ALL, relapsed/refractory non-Hodgkin’s lymphoma, including relapsed/refractory diffuse large B-cell lymphoma.

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Judiciary News Analysis

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

The Supreme Court last week upended one of the underpinnings of administrative law by weakening the authority of federal health agencies to rely on technical expertise as they regulate medical products, issue coverage decisions, and respond to public health crises.

July 05, 2024

Vol.50 No.27

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside

The Supreme Court struck down the Chevron doctrine, removing one of the foundational principles of administrative law and upending the way federal agencies rely on technical subject-matter expertise. What comes next?

July 05, 2024

Vol.50 No.27

By Matthew Bin Han Ong

Guest Editorial Satire

A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.

Sometimes profoundly important public health opportunities are discovered by accident.

July 05, 2024

Vol.50 No.27

By Michael A. Friedman

Cancer History Project Guest Editorial

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

July 05, 2024

Vol.50 No.27

By Katerina A. Politi and Roy S. Herbst

In the Archives

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

In 1998, lung cancer was the leading cause of cancer deaths in the United States, with 160,000 deaths per year. That statistic inspired Matthew Meyerson, who would soon start working at the Dana-Farber Cancer Institute, to specialize in lung cancer.

July 05, 2024

Vol.50 No.27

In Brief

Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center

Elizabeth Comen, a breast cancer oncologist and women’s health specialist known for her contributions in the field, has joined the Breast Cancer Center at NYU Langone Health’s Perlmutter Cancer Center as an associate professor of medicine.

July 05, 2024

Vol.50 No.27

Blinatumomab granted Priority Review in acute lymphoblastic leukemia

YOU MAY BE INTERESTED IN

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside

A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center

Renew today!

Subscriber content

Login

Blinatumomab granted Priority Review in acute lymphoblastic leukemia

YOU MAY BE INTERESTED IN

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside

A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supplyWarning: This is not a public health recommendation. Do not implement.

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center

Login

A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.